
    
      -  Patients with advanced (stage IV, and Stage IIIB with effusion) non-small cell lung
           cancer with non-squamous histology, good performance status, and adequate organ function
           are eligible.

        -  Patients with brain metastases, squamous histology, or hemoptysis are excluded.

        -  All patients must give informed consent.

        -  Schema gemcitabine 1250 mg/M2 IV day 1,8 carboplatin AUC 5 IV day 1 bevacizumab 15 mg/kg
           IV day 1 repeated every 21 days for 6 cycles
    
  